Voriconazole-Induced QT Interval Prolongation: A Prospective Study
- Conditions
- Voriconazole Induced QT Interval Prolongation
- Registration Number
- NCT04502355
- Lead Sponsor
- Rabin Medical Center
- Brief Summary
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- oral or IV treatment with voriconazole
Exclusion Criteria
- No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
- Renal insufficiency or dialysis treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method QT interval prolongation up to three months of treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Schneider childrens medical center of Isreal
🇮🇱Petah Tikva, Israel